期刊文献+

液相色谱串联质谱法测定人血清中匹多莫德的浓度 被引量:3

Determination of Pidotimod in Human Serum by HPLC-MS/MS
下载PDF
导出
摘要 目的:建立液相色谱串联质谱法测定人血清中匹多莫德的浓度。方法:血清样品用甲醇沉淀蛋白,内标为格列吡嗪,色谱柱为LichrospherC18(4.6mm×150mm,5μm),柱温为30℃,流动相为甲醇-2.5mmol/L NH4Ac(90∶10,V/V),流速为0.5mL/min。质谱采用ESI离子源负离子检测,定量分析的离子对为:m/z 242.9/153.0(匹多莫德),m/z 444.0/169.9(内标格列吡嗪)。结果:匹多莫德在0.1~10mg/L范围内线性关系良好(r=0.9995),批内批间RSD均小于15%,提取回收率为85.52%~98.30%。结论:该方法快速,灵敏,准确,可用于匹多莫德的临床药动学研究。 To develop and validate an HPLC-MS/MS for the determination of pidoti- mod in human serum. METHODS. Glipizide was added as internal standard. The sample prepara- tion included a simple deproteinization step withmethanol. Chromatographic separation was a- chieved on a Lichrospher C18 column(4.6 mm)〈 150 mm, 5 μm)at 30 ℃ with the mobile phase consisted of methanol-2.5 mmol/L NH4Ac (90 : 10, V/V). The mobile phase was eluted at aflow rate of 0.5 mL/min. Tandem mass spec- trometer equipped with electrospray ionization source was applied and operated in the negative ion mode. Multiple reaction monitoring using the precursor to product ion combinations of m/ z 242.9/153.0 and m/z 444.0/169.9 was per- formed to quantify pidotimod and glipizide, re- spectively. RESULTS. The calibration curves were linear over the range of 0.1--10 mg/L(r= 0. 9995). RSD of intra-batch and inter-batchwere less than 15%, extraction recovery of three level concentrations were 85.52%- 98.30%. CONCLUSION. The method is shown to be con- venient, accurate, sensitive, and suitable for clinical pharmacokinetic study of pidotimod.
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第3期308-313,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 皖南医学院中青年科研基金(WK200918F)
关键词 匹多莫德 格列吡嗪 LC-MS/MS 药动学 血清 蛋白沉淀 Pidotimod Glipizide LC-MS/MS Pharmacokinetics Serum Deproteinization
  • 相关文献

参考文献8

二级参考文献23

  • 1田新平,曾小峰.新型合成免疫调节剂——匹多莫德[J].中国新药杂志,2005,14(1):111-114. 被引量:97
  • 2赵彩霞.顺尔宁治疗小儿哮喘疗效观察[J].现代医药卫生,2005,21(4):431-431. 被引量:24
  • 3赵志炼,叶进.万乃洛韦联合匹多莫德治疗复发性生殖器疱疹疗效观察[J].中国麻风皮肤病杂志,2005,21(5):372-373. 被引量:10
  • 4张华峰,张福成,王健康,刘延,刘真业,杨汉煜.LC/MS/MS分析方法测定人血浆中匹多莫德的浓度[J].解放军药学学报,2006,22(6):436-438. 被引量:5
  • 5Posavad CM, Wald A, Hosken N, et al. T cell immunity to herpes simplex viruses in seronegative subjects:silent infection or acquired immunity? [J]. J Immunol,2003,170(8) :4380- 4388.
  • 6Singb R, Kumar A, Creery WD, et al. Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection [ J ]. Clin Exp Immunol,2003,133 : 97-107.
  • 7Guerra B, Perino A, Polatti F, et al. Pidotimod in the management of vulvar papillomatousis : double-blind clinical trial versus placebo [ J]. Amer J Ther, 1998,5 (3) : 147-152.
  • 8Rabasseda X.Brivudine:aherpes virostatic with rapid antiviral activity and once-daily dosing.Drugs Today(Barc),2003,39(5):359-371.
  • 9Schmader K.Postherpetle neuralgia in immunocompetent elderly people.Vaccine,1998,16(18):1768-1770.
  • 10Volpi A,Gross G,Hercogova J,et al.Current management of herpes zoster:the European View.Am J Clin Derm atol,2005,6(5):3l7-325.

共引文献46

同被引文献21

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部